Effects of cocktail therapy on TGF-β1, COL I and COL III expression in liver fibrosis in rats

World Chinese Journal of Digestology

Volumn 18, Issue 18, 2010, Pages 1867-1872

  Liao, Ming ^a   Lin, Xing ^a   Chen, Zhao Ni ^a   Li, Yan ^b   Zhuo, Lang ^c  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI UNIVERSITY   (China)

^c INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Cocktail therapy; Liver fibrosis; Liver tissue

Indexed keywords

CARBON TETRACHLORIDE; COCKTAIL THERAPY; COLCHICINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; EPIGALLOCATECHIN GALLATE; GENISTEIN; LIVER PROTECTIVE AGENT; TAURINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 77958087592     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Weng H, Mertens PR, Gressner AM, Dooley S. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007; 46: 295-303 (Pubitemid 44959156)
2. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G631-G639 (Pubitemid 47435392)
3. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335 (Pubitemid 351975556)
4. Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res 2008; 25: 249-258
5. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H, Mertens PR. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008; 135: 642-659
6. Inagaki Y, Higashi K, Kushida M, Hong YY, Nakao S, Higashiyama R, Moro T, Itoh J, Mikami T, Kimura T, Shiota G, Kuwabara I, Okazaki I. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 2008; 134: 1180-1190 (Pubitemid 351451969)
7. Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C. Isoprostanes and hepatic fibrosis. Mol Aspects Med 2008; 29: 43-49
8. Dumont JM, Maignan MF, Janin B, Herbage D, Perrissoud D. Effect of malotilate on chronic liver injury induced by carbon tetrachloride in the rat. J Hepatol 1986; 3: 260-268
9. Chen YX, Zhang XR, Xie WF, Li S. Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat Dis Int 2004; 3: 106-109
10. Kato J, Ido A, Hasuike S, Uto H, Hori T, Hayashi K, Murakami S, Terano A, Tsubouchi H. Transforming growth factor-beta-induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis. Hepatol Res 2004; 30: 34-41
11. Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 2006; 67: 1849-1855
12. Nakamuta M, Higashi N, Kohjima M, Fukushima M, Ohta S, Kotoh K, Kobayashi N, Enjoji M. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int J Mol Med 2005; 16: 677-681
13. Zhen MC, Wang Q, Huang XH, Cao LQ, Chen XL, Sun K, Liu YJ, Li W, Zhang LJ. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J Nutr Biochem 2007; 18: 795-805
14. Giannelli G, Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 2005; 20: 939-944
15. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105
16. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006; 364: 33-60
17. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995; 92: 2572-2576
18. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Büschenfelde KH, Blessing M. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999; 276: G1059-G1068
19. Schnur J, Oláh J, Szepesi A, Nagy P, Thorgeirsson SS. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004; 16: 127-133
20. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99
21. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 Suppl 1: S79-S84
22. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-d807